Pascal Furet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pascal Furet has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Thomas Meyer
Oncology Research, Novartis Pharma AG, CH-4002 Basel, Switzerland
4 shared publicationsBrigitte Gay
Novartis
3 shared publicationsHeinz Fretz
Novartis Pharma Inc
3 shared publicationsJohann Zimmermann
3 shared publicationsJoseph Rahuel
3 shared publicationsJoseph Schoepfer
3 shared publications
Latest Publications
- 1 September 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (18) , 2967-2971
Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching
- 1 September 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (18) , 2967-2971
Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching
- Open Access
- 1 April 2003
- Published by Swiss Chemical Society in Chimia
- Vol. 57 (4) , 179
Non-Covalent Inhibitors of the 20S Proteasome
Peptidomimetics have been commonly used as lead compounds to design inhibitors with high affinity and specificity for a particular enzyme. The discovery that a 2-aminobenzylstatine derivative originally designed to target an aspartyl protease was able to inhibit specifically and non-covalently the chymotrypsin-like activity of the 20S proteasome represented a unique starting point for our medicinal chemistry endeavor for this target. Utilizing a structure-based design approach, we have been able to improve the potency of this new class of proteasome inhibitors without affecting its in vitro selectivity profile.
- 1 April 2003
- Published by Swiss Chemical Society in Chimia
- Vol. 57 (4) , 179
Open AccessNon-Covalent Inhibitors of the 20S Proteasome
Peptidomimetics have been commonly used as lead compounds to design inhibitors with high affinity and specificity for a particular enzyme. The discovery that a 2-aminobenzylstatine derivative originally designed to target an aspartyl protease was able to inhibit specifically and non-covalently the chymotrypsin-like activity of the 20S proteasome represented a unique starting point for our medicinal chemistry endeavor for this target. Utilizing a structure-based design approach, we have been able to improve the potency of this new class of proteasome inhibitors without affecting its in vitro selectivity profile.
- 1 January 2003
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry - Anti-Cancer Agents
- Vol. 3 (1) , 15-23
X-Ray Crystallographic Studies of CDK2, a Basis for Cyclin-Dependent Kinase Inhibitor Design in Anti-Cancer Drug Research
Abstract: Inhibition of cyclin-dependent kinases is a theme of major interest in current anti-cancer agents research. Different classes of chemical inhibitors of these enzymes have been identified during the past decade and the structural basis of inhibition has been elucidated by X-ray crystallography studies of one member of the family, CDK2. In this article, we review the structural biology work that has led to a precise knowledge of the interactions between CDK2 and small organic molecules binding to its ATP pocket that are determinant for inhibitory activity. The use of this information to design or optimize CDK inhibitors by molecular modeling is also reviewed.
- 1 January 2003
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry - Anti-Cancer Agents
- Vol. 3 (1) , 15-23
X-Ray Crystallographic Studies of CDK2, a Basis for Cyclin-Dependent Kinase Inhibitor Design in Anti-Cancer Drug Research
Abstract: Inhibition of cyclin-dependent kinases is a theme of major interest in current anti-cancer agents research. Different classes of chemical inhibitors of these enzymes have been identified during the past decade and the structural basis of inhibition has been elucidated by X-ray crystallography studies of one member of the family, CDK2. In this article, we review the structural biology work that has led to a precise knowledge of the interactions between CDK2 and small organic molecules binding to its ATP pocket that are determinant for inhibitory activity. The use of this information to design or optimize CDK inhibitors by molecular modeling is also reviewed.
- 1 May 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (10) , 1331-1334
Structure-Based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-Like activity of the human 20S proteasome
- 1 May 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (10) , 1331-1334
Structure-Based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-Like activity of the human 20S proteasome
- 1 January 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (2) , 221-224
Structure-based design and protein X-ray analysis of a protein kinase inhibitor
- 1 January 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (2) , 221-224
Structure-based design and protein X-ray analysis of a protein kinase inhibitor
- 1 May 2001
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 15 (5) , 489-495
Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching
We have selected cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, as a target in our efforts to discover new antitumor agents. By exploiting available...
- 1 May 2001
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 15 (5) , 489-495
Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching
We have selected cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, as a target in our efforts to discover new antitumor agents. By exploiting available...
- 1 May 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (10) , 1321-1324
Modeling of the Binding Mode of a Non-covalent Inhibitor of the 20S Proteasome. Application to Structure-Based Analogue Design
- 1 May 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (10) , 1321-1324
Modeling of the Binding Mode of a Non-covalent Inhibitor of the 20S Proteasome. Application to Structure-Based Analogue Design
- 1 October 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (20) , 2337-2341
Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1
- 1 October 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (20) , 2337-2341
Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1
- 1 July 2000
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 14 (5) , 403-409
Structure-based design of potent CDK1 inhibitors derived from olomoucine
Cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, constitutes a possible target in the search for new antitumor agents. Starting from the purine...
- 1 July 2000
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 14 (5) , 403-409
Structure-based design of potent CDK1 inhibitors derived from olomoucine
Cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, constitutes a possible target in the search for new antitumor agents. Starting from the purine...
- 9 June 1999
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (13) , 2358-2363
Structure-Based Design, Synthesis, and X-ray Crystallography of a High-Affinity Antagonist of the Grb2-SH2 Domain Containing an Asparagine Mimetic
Previous efforts in the search for molecules capable of blocking the associations between the activated tyrosine kinase growth factor receptors and the SH2 domain of Grb2 had resulted in the identification of 3-amino-Z-pTyr-Ac6c-Asn-NH2, a high-affinity and selective antagonist of this SH2 domain. In the present paper, we report the successful replacement of asparagine in this compound by a beta-amino acid mimetic, which brings us closer to our objective of identifying a Grb2-SH2 antagonist suitable for pharmacological investigations.
- 9 June 1999
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (13) , 2358-2363
Structure-Based Design, Synthesis, and X-ray Crystallography of a High-Affinity Antagonist of the Grb2-SH2 Domain Containing an Asparagine Mimetic
Previous efforts in the search for molecules capable of blocking the associations between the activated tyrosine kinase growth factor receptors and the SH2 domain of Grb2 had resulted in the identification of 3-amino-Z-pTyr-Ac6c-Asn-NH2, a high-affinity and selective antagonist of this SH2 domain. In the present paper, we report the successful replacement of asparagine in this compound by a beta-amino acid mimetic, which brings us closer to our objective of identifying a Grb2-SH2 antagonist suitable for pharmacological investigations.